Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite   ... technical and medical information products and services, announced today the ... clinical decision support (CDS) technology company. InferMed,s Arezzo ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing ... from the Ministry of Health, Labour and Welfare Kinki Bureau ... The fact that R- Japan received ... Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 ... stem cell manufacturing service to medical institutions. As of November ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... Group today released its syndicated report TreatmentTrends ... the fourth annual survey of U.S. Dermatologists (n=150). The ... April, highlights shifting trends in the management of psoriasis and ... mild, moderate, and severe patients with an emphasis on the ...
... GAITHERSBURG, Md., May 28 GenVec, Inc. (Nasdaq: ... purchase agreement with a single institutional investor for the sale of ... shares of its common stock. The shares of common stock ... of common stock and a warrant to purchase one share of ...
... researchers at the University of Illinois has demonstrated that, ... superconducting electrons in an ultrathin superconducting wire is able ... a higher electrical current to one with a notably ... macroscopic quantum tunneling. , Physics professors Alexey Bezryadin and ...
Cached Biology Technology:Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3Evidence of macroscopic quantum tunneling detected in nanowires 2
(Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Millions of patients suffering from liver,damage (cirrhosis) and ... Edinburgh and Southampton which may lead to new,life-saving ... cirrhosis,and a patient's only hope of survival is ... the University's Centre for Inflammation,Research, in collaboration with ...
... of Oregon have,discovered a form of blue-green algae ... light for photosynthesis,according to an article published in ... National Academy of Sciences (PNAS).,"This new strain of ... live,on its own," says UO biology professor Michelle ...
... work, scientists have now found that changes in a single ... fish living in the wild. , The surprising results, announced ... new data to long-standing debates about how evolution occurs in ... how new animal types evolve in nature," said molecular geneticist ...
Cached Biology News:Research Gives Hope For Liver Damage 2Scientists discover unique microbe in California's largest lake 2Scientists discover unique microbe in California's largest lake 3Scientists discover unique microbe in California's largest lake 4Scientists discover unique microbe in California's largest lake 5Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 2Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 3Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 4Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 5